Please login to the form below

Not currently logged in
Email:
Password:

Gonal-f

This page shows the latest Gonal-f news and features for those working in and with pharma, biotech and healthcare.

Merck's pharma unit faces tougher 2017 as fertility boost recedes

Merck's pharma unit faces tougher 2017 as fertility boost recedes

company. Throughout 2016 Merck's Gonal-f fertility drug has benefited from reduced competition from Ferring's Bravelle range, which was pulled from the US market last year because of quality ... issues. In the third quarter Gonal-f grew 10% to 182m, a

Latest news

  • Merck completes €15m Spanish biotech facility expansion Merck completes €15m Spanish biotech facility expansion

    The Tres Cantos plant is Merck's main site for the production of active substances in its fertility treatment Gonal-f and endocrine and metabolic disorders treatment Saizen, for which global ... Merck was able to raise its sales forecast for 2016 earlier

  • Fertility drugs drive healthcare growth at Merck KGaA Fertility drugs drive healthcare growth at Merck KGaA

    Fertility drugs drive healthcare growth at Merck KGaA. Strong performances from Gonal-f and Rebif boost the firm’ s 2016 sales forecast. ... In particular, the group's portfolio of fertility treatments put in a stellar performance, headed by Gonal-f

  • Roche and Merck boost manufacturing capacity Roche and Merck boost manufacturing capacity

    for a number of Merck Serono drugs, including brands such as Gonal-f (follitropin-alfa) used to treat fertility. ... Gonal-f was its fastest-growing product, with sales up 11 per cent to 152m in the quarter.

  • Sales down at Merck Serono on Rebif pressure Sales down at Merck Serono on Rebif pressure

    Among its other products, sales of Merck Serono's fertility treatment Gonal-f (follitropin alfa) slipped fractionally to 137m while growth hormone Saizen (somatropin) brought in 61m, in line with one

  • Merck KGaA to meet 2014 financial targets one year early Merck KGaA to meet 2014 financial targets one year early

    This performance helped offset declines for other key brands, such as fertility treatment Gonal-f (follitropin alfa) and growth hormone product Saizen (somatropin), down 4 and 8 per cent to 145m

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics